Moderate to Severe Chronic Plaque Psoriasis: Clinical Trials

18 trials for Moderate to Severe Chronic Plaque Psoriasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 1 unknown, 1 withdrawn. 10 Phase 3, 4 Phase 2, 2 Phase 1, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 310Completed 10
Phase 24Completed 3, Unknown 1
Phase 12Completed 1, Unknown 1
Phase 41Completed 1

Follow Moderate to Severe Chronic Plaque Psoriasis: new trials by email Literature Review of Moderate to Severe Chronic Plaque Psoriasis trials Research Report on Moderate to Severe Chronic Plaque Psoriasis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).
Bmab 1200 (Biosimilar Ustekinumab) - Moderate to Severe Chronic Plaque Psoriasis
Phase 1CompletedBiocon Biologics UK Ltd1862025-01-092025-08-19
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
Infliximab-dyyb Biosimilar (Remsima) - Moderate to Severe Chronic Plaque Psoriasis
Phase 1 / Phase 2UnknownServices Institute of Medical Sciences, Pakistan1042023-11-062024-09-19
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
Placebo, Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL1332023-10-312026-11-18
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis
JS005 (recombinant humanized monoclonal antibody against IL-17A) - Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedShanghai Junshi Bioscience Co., Ltd.7472023-08-282025-12-16
To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
CT-P17, EU-approved Humira - Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedCelltrion3672022-11-072024-08-21
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
Cosentyx - Moderate to Severe Chronic Plaque Psoriasis
CompletedNovartis Pharmaceuticals422022-09-082025-12-29
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
Stelara, Bmab1200 - Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedBiocon Biologics UK Ltd3842022-06-282025-09-12
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
DMB-3115, Stelara - Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedDong-A ST Co., Ltd.5982021-04-282024-01-18
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL1722018-12-202025-07-14
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL13532018-09-052026-04-15
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab, Secukinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL7432018-06-132026-04-15
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL4352018-02-052026-04-15
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab, Ustekinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL5672017-12-062026-04-15
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis
AbGn-168H, Placebo - Moderate to Severe Chronic Plaque Psoriasis
Phase 2CompletedAbGenomics B.V Taiwan Branch502014-05-012016-04-14
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
AbGn-168H, placebo - Moderate to Severe Chronic Plaque Psoriasis
Phase 2CompletedAbGenomics B.V Taiwan Branch542013-05-012015-05-08
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
Moderate to Severe Chronic Plaque Psoriasis
WithdrawnAbbVie (prior sponsor, Abbott)2013-02-012016-11-29
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
Doxercalciferol, Placebo - Moderate to Severe Chronic Plaque Psoriasis
Phase 2CompletedGenzyme, a Sanofi Company1112008-04-012014-05-05
Community Based Trial for AMEVIVE®
Alefacept - Moderate to Severe Chronic Plaque Psoriasis
Phase 4CompletedAstellas Pharma Inc1142004-07-012014-09-08

Narrower conditions

Psoriasis (10)  ·  Arthritis, Psoriatic (2)

Broader conditions

Skin Diseases (10)  ·  Skin Diseases, Papulosquamous (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Arthritis (2)  ·  Bone Diseases (2)  ·  Joint Diseases (2)  ·  Musculoskeletal Diseases (2)  ·  Spinal Diseases (2)  ·  Spondylarthritis (2)  ·  Spondylarthropathies (2)  ·  Spondylitis (2)

Interventions

bimekizumab (6)  ·  Ustekinumab (3)  ·  secukinumab (2)  ·  1 alpha-hydroxyergocalciferol (1)  ·  Alefacept (1)  ·  CT-P13 (1)  ·  CT-P17 (1)

Sponsors

UCB Biopharma SRL (6)  ·  AbGenomics B.V Taiwan Branch (2)  ·  Biocon Biologics UK Ltd (2)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Astellas Pharma Inc (1)  ·  Celltrion (1)  ·  Dong-A ST Co., Ltd. (1)  ·  Genzyme, a Sanofi Company (1)  ·  Novartis Pharmaceuticals (1)  ·  Services Institute of Medical Sciences, Pakistan (1)  ·  Shanghai Junshi Bioscience Co., Ltd. (1)

Countries

United States (11)  ·  Canada (5)  ·  Australia (4)  ·  Germany (4)  ·  Poland (4)  ·  United Kingdom (4)  ·  Belgium (3)  ·  China (3)  ·  Hungary (3)  ·  Russia (3)  ·  Italy (2)  ·  Japan (2)  ·  South Korea (2)  ·  Estonia (1)  ·  France (1)

Top investigators

Mark Lebwohl, MD (2)  ·  Dr Hira Tariq, MBBS, FCPS Derma (1)  ·  Michael Gold (1)  ·  Natali Serra-Bonett, MD (1)  ·  Shih-Yao Lin, MD, Ph.D (1)  ·  Shih-Yao Lin, MD, PhD (1)

Results publications

PMID 39578348, PMID 41060492, PMID 41800601, PMID 35544084, PMID 36751950, PMID 37950894, PMID 40286813, PMID 40886218, PMID 41359217, PMID 41580158, PMID 34260044, PMID 38588819, PMID 33549192, PMID 33549193, PMID 33891380, PMID 34001692, PMID 34471992, PMID 35133113, PMID 36648594, PMID 36689515, PMID 37182701, PMID 39285121, PMID 39862230, PMID 39932677, PMID 40148673, PMID 40156698, PMID 40708530, PMID 40788331, PMID 41100115, PMID 41678327, PMID 41706476, PMID 42643157

NIH funding

2016 (3), 2017 (1)